We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $49.65 · 17 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Exelixis (EXEL) Reports Positive Phase 3 Trial Results for Cabom - GuruFocus
Exelixis (EXEL) Reports Positive Phase 3 Trial Results for Cabom GuruFocus
Exelixis, Inc. (EXEL): Renaissance Technologies Likes This Stock - Yahoo Finance
Exelixis, Inc. (EXEL): Renaissance Technologies Likes This Stock Yahoo Finance
Exelixis presents Cabometyx data for neuroendocrine tumors By Investing.com - Investing.com Australia
Exelixis presents Cabometyx data for neuroendocrine tumors By Investing.com Investing.com Australia
Should New ASCO Colorectal Cancer Data on Zanzalintinib Reshape Exelixis' (EXEL) Investment Narrative? - simplywall.st
Should New ASCO Colorectal Cancer Data on Zanzalintinib Reshape Exelixis' (EXEL) Investment Narrative? simplywall.st
Exelixis says Cabometyx reduces risk of progression or death by 74% in non-functional net, 60% in functional net - marketscreener.com
Exelixis says Cabometyx reduces risk of progression or death by 74% in non-functional net, 60% in functional net marketscreener.com
Exelixis Says Cabometyx Reduces Risk Of Progression Or Death By 74% In Non-Functional Net, 60% In Functional Net - TradingView
Exelixis Says Cabometyx Reduces Risk Of Progression Or Death By 74% In Non-Functional Net, 60% In Functional Net TradingView
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | After market close (AMC) | $0.86 | — | — | $632.03M | — | Scheduled |
| FY2026 Q1 | 2025. 04. 04. | Time TBD | — | $0.55 | — | — | $555.45M | Reported |
| FY2025 Q3 | 2024. 09. 27. | Time TBD | — | $1.28 | — | — | $1.6B | Reported |
| FY2025 Q2 | 2024. 06. 28. | Time TBD | — | $0.88 | — | — | $1.06B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 07. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 07. | TD Cowen | — | Maintain | Buy → Buy | — | TD Cowen: Buy |
| 2026. 05. 07. | Morgan Stanley | — | Maintain | Equal-Weight → Equal-Weight | — | Morgan Stanley: Equal-Weight |
| 2026. 05. 07. | Stifel | — | Maintain | Hold → Hold | — | Stifel: Hold |
| 2026. 05. 06. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2026. 04. 20. | Barclays | — | Maintain | Equal-Weight → Equal-Weight | — | Barclays: Equal-Weight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 2,206,212 | $94.62B | 0.08% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 855,980 | $37.52B | 0.06% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 273,791 | $12B | 0.02% | — | New position |